CD74 Antikörper
Kurzübersicht für CD74 Antikörper (ABIN7865650)
Target
Alle CD74 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Verwendungszweck
- anti-CD74 mouse monoclonal, LN-2, purified
-
Kreuzreaktivität (Details)
- negative with rat
-
Aufreinigung
- affinity chromatography
-
Immunogen
- cell extracts from diffuse histiocytic lymphoma SU-DHL-4
-
Isotyp
- IgG1 kappa
-
-
-
-
Applikationshinweise
-
ICC/IF_dilution: 1:100-1:200 (0.5-1.0 μg/mL)
FACS_dilution: 0.5-1.0 μg/million cells in 0.1 ml
IHC-paraffin_dilution: 1:50-1:100 (1-2 μg/mL, microwave treatment in 10 mM citrate buffer pH 6.0 recommended)
IHC-frozen_dilution: 1:50-1:100 (1-2 μg/mL)
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 100 μg/mL
-
Buffer
- PBS with 0.02 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- store at 2 - 8 °C
-
-
- CD74 (HLA-DR-gamma (CD74))
-
Andere Bezeichnung
- CD74
-
Hintergrund
- LN-2 is directed against the CD74 cluster, established during the IVth Leukocyte Typing Workshops. CD74 comprises four species of proteins (MW 41/35/33 kDa), all coded by a single gene, consisting of nine exons. CD74 is expressed primarily by antigen presenting cells, such as B-lymphocytes (from before the pre-B cell stage to before the plasma cell stage), macrophages, and monocytes, and many epithelial cells. In tissue sections anti CD74 show a binding pattern very similar to that of anti-HLA-DR. It binds to the peptide binding groove of newly synthesized MHC class II alpha/beta heterodimers and prevents their premature association with endogenous polypeptides. Positive control: Daudi or Raji cells. Tonsil or lymp node.
-
Pathways
- Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Negative Regulation of intrinsic apoptotic Signaling, Cancer Immune Checkpoints
Target
-